SUBSCRIBE
SUBSCRIBE
News   Business

Incyte Corporation Arthritis Drug Shows Promise; Positive Phase 2 Data Triggers $30 Million Milestone from Eli Lilly and Company

May 6, 2010 | 
1 min read

Reuters -- Biotechnology firm Incyte Corp said data from a mid-stage trial of its experimental rheumatoid arthritis treatment showed the drug was safe and effective.

Alliances Clinical research Phase II
Eli Lilly and Company Incyte
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Stubborn Layoff Trend Continues Across Biopharma in 2024
December 23, 2024
 · 
207 min read
 · 
BioSpace Editorial Staff
Recession arrow, Graph showing business decline on led screen
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
December 20, 2024
 · 
1 min read
 · 
Kate Goodwin
GSK's headquarters office building in Poznan, Poland
Ovarian cancer
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
December 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Corporate headquarters of Novo Nordisk in Denmark
Obesity
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
December 20, 2024
 · 
3 min read
 · 
Tristan Manalac